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http://www.biomedcentral.com/1471-2407/14/826RESEARCH ARTICLE Open AccessLobular breast cancers lack the inverse relationship
between ER/PR status and cell growth rate
characteristic of ductal cancers in two
independent patient cohorts: implications for
tumor biology and adjuvant therapy
Hilda Wong1, Silvia Lau2, Polly Cheung3, Ting Ting Wong3, Andrew Parker4, Thomas Yau1* and Richard J Epstein5,6Abstract
Background: Although invasive lobular carcinoma (ILC) of the breast differs from invasive ductal carcinoma (IDC) in
numerous respects - including its genetics, clinical phenotype, metastatic pattern, and chemosensitivity - most experts
continue to manage ILC and IDC identically in the adjuvant setting. Here we address this discrepancy by comparing
early-stage ILC and IDC in two breast cancer patient cohorts of differing nationality and ethnicity.
Methods: The clinicopathologic features of 2029 consecutive breast cancer patients diagnosed in Hong Kong (HK) and
Australia (AUS) were compared. Interrelationships between tumor histology and other clinicopathologic variables,
including ER/PR and Ki67, were analysed.
Results: Two hundred thirty-nine patients were identified with ILC (11.8%) and 1790 patients with IDC. AUS patients
were older (p <0.001) and more often postmenopausal (p <0.03) than HK patients. As expected, ILC tumors were lower
in grade and proliferative rate, and more often ER-positive and HER2-negative, than IDC (p <0.002); yet despite this, ILC
tumors were as likely as IDC to present with nodal metastases (p >0.7). Moreover, whereas IDC tumors exhibited a
strongly negative relationship between ER/PR and Ki67 status (p <0.0005), ILC tumors failed to demonstrate any such
inverse relationship (p >0.6).
Conclusion: These data imply that the primary adhesion defect in ILC underlies a secondary stromal-epithelial
disconnect between hormonal signaling and tumor growth, suggesting in turn that this peritumoral feedback
defect could reduce both the antimetastatic (adjuvant) and tumorilytic (palliative) efficacy of cytotoxic therapies
for such tumors. Hence, we caution against assuming similar adjuvant chemotherapeutic survival benefits for ILC
and IDC tumors with similar ER and Ki67, whether based on immunohistochemical or gene expression assays.Background
The advent of molecular genomics is ushering in a new
paradigm of personalised cancer management in which
treatments come to match biomarker-defined tumor sub-
types [1]. A prime example of such a tumor subtype is
invasive lobular carcinoma (ILC) of the breast - the second
commonest histology after invasive ductal carcinoma* Correspondence: the@netvigator.com
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unless otherwise stated.(IDC) - which accounts for 5-15% of primary breast
tumors and, unlike IDC, is rising in frequency [2]. Com-
pared to IDCs, ILCs tend to be larger and lower grade
[3]; less FDG-avid on PET scanning [4]; less often asso-
ciated with vascular invasion [5], angiogenic growth
factor expression or stromal reaction [3]; more often
node-positive and metastatic [6], especially to bone or
serosal surfaces [7]; and more resistant to chemotherapy
[8] despite less frequent TP53 gene mutations [9]. The
signature of ILC on gene expression profiling also dif-
fers from that of grade-/subtype-matched IDC [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mediated by the epithelial cadherin-catenin complex, as
diagnostically confirmed by absent immunochemical
detection of the transmembrane E-cadherin protein.
This ILC adhesion defect is constitutive, often reflecting
frameshift mutations of the CDH1 gatekeeper tumor
suppressor gene that cause truncation of the E-cadherin
extracellular domain, together with loss of heterozygosity
for the wild-type allele [11]. The accompanying defect in
ILC adhesion gives rise to the typical histopathologic
appearance of strand-like 'single-file' tumor cells and/or
discohesive signet ring cells within a stroma lacking
tissue reaction, a phenotype in turn attributable to
reduced stromal-epithelial crosstalk by transforming
growth factor-beta [10]. This lack of stromal reaction
may underlie the lower palpability of ILC compared to
IDC, contributing to the larger size of ILC tumors [12].
Given this convincing spectrum of clinicopathologic
and molecular differences [13], it may seem surprising
that current orthodoxies still support identical stage-
specific adjuvant management of ILC and IDC [7,14].
An increasing number of reports have highlighted that
the apparently favorable ('luminal-like' [15]) phenotype
of ILC tumors - namely, low nuclear grade, high ER-
positivity, absent HER2, CCND1 and TOP2A amplifica-
tion, and low growth rates [15,16] - fails to translate
into survival benefit relative to IDCs, whether stage-
matched or not [17]. Other studies have suggested a
similar overall prognosis in ILC and IDC [3,12,14],
though this conclusion could misleadingly reflect (i)
a superior stage-matched 5-year survival for ILC [18]
balanced by a longer-term overall survival advantage for
IDC due to less frequent late metastatic relapses [5], or
(ii) a worse prognosis for node-positive ILC than IDC
offset by a relatively better prognosis for node-negative
ILC [19].
To resolve these discrepancies, at least some of which
could reflect confounding by sample heterogeneity, the
present study compares ILC tumor characteristics with
those of IDC controls in two independent cohorts from
countries with divergent epidemiology. Specifically, the
natural history of breast cancer in Australia (AUS)
mimics that of developed Western countries in Europe
or North America, whereas the rising breast cancer
incidence in younger Hong Kong (HK) Chinese patients
reflects a recent lifestyle-dependent cohort effect [20,21].
Here we exploit this dual-sample comparison to frame a
systematic interrogation of the functional interrelation-
ships between ILC and IDC tumor parameters.
Methods
We analyzed cohorts of consecutive primary breast cancer
patients treated at either the Hong Kong Sanatorium
and Hospital in 2001–2011, or at St. Vincent’s Hospital,Sydney in 2007–2012. Patients with metastatic disease,
or pathological subtypes other than ILC and IDC, were
excluded. All patients were treated with curative intent,
consisting of mastectomy or breast conservation, followed
by external beam radiotherapy and/or systemic adjuvant
therapy. Eligible patients were then classified according to
geography and histology into ILC and IDC groups from
HK (denoted by HK-ILC and HK-IDC, respectively) vs.
those from AUS (AUS-ILC, AUS-IDC). Demographics,
clinicopathological data including tumor size, grade, lym-
phovascular infiltration, lymph node involvement, ER, PR
and HER2 status and Ki67 (cell proliferation) status,
together with survival durations where available, were
recorded. The access to the clinical databases used in
this study was permitted by the ethics committee of
both Queen Mary Hospital, Hong Kong and St Vincent’s
Hospital, Sydney, Australia.
Tumor histology and the number of involved lymph
nodes were evaluated by hematoxylin-eosin staining.
Immunohistochemistry (IHC) was performed using com-
mercial kits on formalin-fixed, paraffin-embedded speci-
mens. In the HK tumor samples, IHC of ER and PR was
assessed using 6 F11 and 1A6 antibodies respectively, and
detected by the polymer EnVision system (Dako, Glostrup,
Denmark). Expression of ER and PR were graded by the
semi-quantitative H-score, where a score of over 50 out of
300 was interpreted as positive. In the AUS samples, the
antibodies SP1 and 1E2 stained on Ventana Ultra platform
(Ventana Medical Systems, Tucson, Arizona, USA) were
used in IHC of ER and PR respectively. According to AUS
criteria, positivity was defined as nuclei staining of 1% or
more. HER2 IHC assays used in HK and AUS samples
were A0485 (Dako) and 4B5 (Ventana) respectively. HER2
positivity was defined by IHC 3+ (strong positive staining
on at least 10% of breast tissue specimen) and/or fluor-
escent in situ hybridization (FISH)-amplified (HER2
DNA to chromosome 17 centromere DNA ratio of at
least 2.2), the latter using using PathVysion Vysis FISH
(Abbott, Chicago, IL, USA). Both IDC and ILC tumors
were graded using modified Bloom & Richardson scoring
criteria, viz., summation of scores (1–3) for nuclear
morphology, tubule formation, and mitotic score; the
latter parameter correlates best with both Ki67 score
and disease prognosis [22,23]. Expression of Ki67 was
assessed in Hong Kong tumor samples using the anti-
body SP6 (Neomarkers/LabVision), a rabbit monoclonal
antibody, which provides similar accuracy, reproducibility
and prognostic value when compared to MIB1 in primary
breast cancer [24,25]. For the Sydney series we used the
30–9 (Ventana, Roche group) antibody which is another
FDA-approved rabbit monoclonal IgG directed against
the C-terminal portion of the Ki67 protein, leading to
selective immunostaining of non-resting, i.e., non-G0,
cells (www.ventanamed.com). For both patient sample
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periphery of each tumor; the percentage of nuclei staining
was quantified in both series using manual Ki67 scoring of
whole sections from excision specimens (and not from
digital image analysis) according to the guidelines pub-
lished by Dowsett M et al. [26]. In both cohorts, tumor
samples were arbitrarily categorised by Ki67 levels into
separate high (>10%) and low (<5%) groups to facilitate
clear qualitative comparison. E-cadherin immunostaining
was routinely used as one of the key parameters, though
not the only such parameter, distinguishing ILC from IDC
morphologic diagnoses.
Summary statistics were used to quantify patient
demographics. The chi-square and Mann–Whitney-U
tests were performed to assess the relationship between
ordinal and numerical variables, respectively. Demo-
graphics and clinicopathological characteristics of the
HK-ILC and AUS-ILC groups were compared; these
groups were also contrasted with the respective IDC
cohorts from the same geographical location. We used
bivariate analysis – a specific subtype of multivariate
analysis which, unlike univariate analysis, is not simply
descriptive – to test the causal relationship between
two clinicopathologic variables - Ki67 and ER/PR status -
pertinent to the distinct disease biologies of ILC and
IDC (see Discussion). To aid clinical decision-making,
we streamlined this bivariate analysis by partitioning
the latter continuous variables into non-parametric
positive/negative (ER/PR) vs. high/low (Ki-67), permit-
ting a Pearson's chi-square computation. Moreover,
to minimise the risk of identifying a chance retrospect-
ive statistical association, all calculations on the total
cohort were repeated in the two (HK and AUS) in-
dependent sub-cohorts. Calculations were performed
using the statistical software SPSS, version 18, and sig-
nificance inferred at p <0.05.
Results
A total of 2029 patients was analyzed. The number of
patients in the HK-ILC, HK-IDC, AUS-ILC and AUS-
IDC groups were 141, 1159, 98 and 631 respectively. All
were female. As shown in Table 1, the median age at
presentation of the AUS-ILC patients was 64, compared
to 50 for HK-ILC patients (p <0.0005); as expected, more
AUS-ILC patients were post-menopausal (p =0.029). The
size of the primary tumor (median 2.4 cm and 2.5 cm re-
spectively for AUS-ILC and HK-ILC groups, p =0.825)
and the proportion of patients with regional lymph node
involvement (47.1% and 40.0% respectively, p =0.299) were
similar in both cohorts. As in earlier studies, ILC tumors
tended to be ER-positive, PR-positive and HER2-negative;
although these expression patterns were not significantly
different between the AUS-ILC and HK-ILC groups, a
trend towards more frequent ER- and PR-negativity wasevident in the younger HK cohort (p <0.09). In contrast,
HER2 positivity was equally uncommon in both ILC
cohorts (5.4 vs. 6.6%, p =0.71); this was also the case
for median Ki67 levels (5% vs. 6% in AUS-ILC and HK-
ILC patients, respectively; p =0.746), with the propor-
tions of patients with high (≥10%) and low (≤5%) Ki67
similar (p =0.293).
Comparison of ILC with IDC controls
As shown in Table 2, patients with ILC were more fre-
quently postmenopausal than those with IDC in both
the HK and AUS cohorts (p ≤0.003). Primary ILC tu-
mors were both larger and of lower grade than IDC in
both patient cohorts (all p <0.0005), but there was no
ILC/IDC difference in the proportion of patients with
lymph node metastases (p >0.7). ILC tumors in both
cohorts were more often ER-positive (p ≤0.001), HER2-
negative (p <0.02) and low-Ki67 (p ≤0.002) than the cor-
responding IDC tumors. While a trend towards more
frequent PR-positivity for ILC than IDC tumors was
noted in the older AUS cohort (84.8 vs. 76.6%; p <0.08),
no such trend was demonstrable for HK-ILC over HK-
IDC (75.4 vs. 72.7%, p >0.5).
Relationship between Ki67 and clinicopathological
features in ILC and IDC
An analysis of tumor parameters in terms of prolifera-
tion rate, as defined by Ki67 high (≥10%) and low (≤5%)
cutoffs, is shown for ILC and IDC in Tables 3 and 4
respectively. A direct correlation between Ki67 and ei-
ther tumor size, lymph node metastasis, or HER2 status
was evident in both ILC and IDC cohorts when com-
bined. This relationship did not reach statistical signifi-
cance for the individual AUS-ILC (p <0.06) or HK-ILC
cohorts (p <0.09) with respect to tumor size, perhaps
reflecting lower numbers relative to IDC counterparts,
nor for the AUS-ILC cohort with respect to HER2 status
(p =0.28); however, the latter value reduced to p =0.06
following age correction, suggesting confounding due to
very low numbers (one case only) of HER2-positive ILC
in the older AUS cohort. In contrast to the above-
mentioned similar Ki67 correlations in ILC and IDC,
there was a highly significant inverse relationship be-
tween ER/PR status and high-Ki67 subset for IDC in
both cohorts (p ≤0.002; Table 4), but no significant rela-
tionship between ER or PR status and high/low Ki67
subset for ILC irrespective of whether evaluated separ-
ately or together (p >0.6; Table 3).
Discussion
The central insight from this international dual-cohort
comparison of ILC and IDC tumor parameters is that
the strongly inverse relationship long noted between ER/
PR and Ki67 immunohistochemistry in IDC [27] appears
Table 1 Comparison of patient demographics and tumor characteristics of AUS-ILC and HK-ILC cohorts
No. of patients (%)
Characteristics All ILC AUS-ILC HK-ILC p
Age at diagnosis
Median (range) 55 (34 – 86) 64 (34 – 86) 50 (34 – 82) <0.0005
<= 35 2 (0.9%) 1 (1.1%) 1 (0.7%)
36 - 50 84 (36.2%) 14 (14.9%) 70 (49.6%)
≥ 51 146 (62.9%) 79 (84.0%) 67 (48.6%)
Menopausal status
Pre-menopausal 39 (30.5%) 8 (18.2%) 31 (36.9%) 0.029
Post-menopausal 89 (69.5%) 36 (81.8%) 53 (63.1%)
Tumor size (cm)
Median (range) 2.4 (0.18 – 20.0) 2.4 (0.5 – 20.0) 2.5 (0.18 – 10.1) 0.825
LN involvement
Negative 129 (57.3%) 45 (52.9%) 84 (60.0%) 0.299
Positive 96 (42.7%) 40 (47.1%) 56 (40.0%)
ER
Negative 12 (5.2%) 2 (2.2%) 10 (7.2%) 0.089
Positive 220 (94.8%) 91 (97.8%) 129 (92.8%)
PR
Negative 48 (20.9%) 14 (15.2%) 34 (24.6%) 0.085
Positive 182 (79.1%) 78 (84.8%) 104 (75.4%)
HER2
Negative 191 (94.1%) 85 (93.4%) 106 (94.6%) 0.71
Positive 12 (5.9%) 6 (6.6%) 6 (5.4%)
Ki67 (%)
Median 5.0 5.0 6.0 0.746
≤ 5 83 (50.6%) 17 (54.8%) 66 (49.6%)
6 - 9 32 (19.5%) 0 (0.0%) 32 (24.1%)
≥ 10 49 (29.9%) 14 (45.2%) 35 (26.3%)
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critical single molecular prognosticator in breast cancer,
even when compared with costlier multigene expression
profiling [28], the Ki67 proliferative index is at once a
negative correlate of disease-free survival and overall
survival [29,30] and a strong predictor of initial response
to chemotherapy - although these inferences can only be
applied to IDC at present.
Some retrospective studies have reported improved
survival of ILC patients relative to IDC patients, con-
cluding that ILC responds better to adjuvant hormone
therapy [31], though such non-randomised observations
are weakened by the possibility that ILC patients may be
at lower overall risk than IDC patients. Consistent with
this possibility, it is now recognised that breast cancers
such as IDC and ILC evolve via multiple pathways involv-
ing different combinations of molecular variables such asTP53 gene mutations (commoner in IDC than ILC; see
above) and/or mTOR pathway activation (commoner in
ILC than IDC; see below).
Recent molecular ER technologies have clarified the
differential isoform (ER-α and -β) contributions to overall
breast tumour ER-positivity. Whereas ER-α drives prolifer-
ation of mammary epithelial cells, implying a valid thera-
peutic target, ER-β is associated with differentiation of
normal breast cells [32], mediates the preventive benefits
of exercise and parity [33] on breast cancer incidence, and
may directly inhibit breast cancer progression [34]. Unlike
IDCs, however, in which both ER-α and -β tend to be
similarly co-expressed, ILCs display a reciprocal relation-
ship between ER-α and ER-β, with abnormally high ER-α
levels but subnormal expression of ER-β [35]. The pro-
differentiation action of ER-β is mediated in part via
direct transcriptional upregulation of E-cadherin, in
Table 2 Contrast of patient demographics and tumor characteristics of ILC against IDC, as stratified by geographical location
Characteristics All ILC All IDC Sp. Cor. p AUS-ILC AUS-IDC Sp. Cor. p HK-ILC HK-IDC Sp. Cor. p
Menopausal status (pre-, post-menopausal, MP) −0.155 <0.0005 −0.160 0.003 −0.135 <0.0005
No. (%) Post-MP 89 (69.5%) 601 (41.3%) 36 (81.8%) 174 (58.6%) 53 (63.1%) 427 (36.8%)
Tumor size (≤2, >2-5, >5 cm) −0.148 <0.0005 −0.145 <0.0005 −0.150 <0.0005
Median (cm) 2.4 1.8 2.4 1.8 2.5 1.8
Tumor grade (1,2,3) 0.205 <0.0005 0.138 <0.0005 0.239 <0.0005
No. (%) Grade 3 14 (6.5%) 873 (49.5%) 8 (8.5%) 275 (44.3%) 6 (4.9%) 598 (52.3%)
LN involvement (no, yes) −0.007 0.761 0.007 0.852 −0.011 0.706
No. (%) Positive 96 (42.7%) 711 (41.6%) 40 (47.1%) 273 (48.1%) 56 (40.0%) 438 (38.4%)
ER (negative, positive) −0.121 <0.0005 −0.131 0.001 −0.114 <0.0005
No. (%) Positive 220 (94.8%) 1416 (80.3%) 91 (97.8%) 512 (84.6%) 129 (92.8%) 904 (78.0%)
PR (negative, positive) −0.037 0.096 −0.067 0.079 −0.018 0.511
No. (%) Positive 182 (79.1%) 1301 (74.0%) 78 (84.8%) 458 (76.6%) 104 (75.4%) 843 (72.7%)
HER2 (negative, positive) 0.095 <0.0005 0.091 0.018 0.093 0.001
No. (%) Negative 210 (91.7%) 1383 (80.3%) 85 (93.4%) 482 (84.0%) 125 (90.6%) 901 (78.5%)
Ki67 (≤5, 6–9, ≥10) 0.269 <0.0005 0.191 0.002 0.252 <0.0005
Median 5 15 5 15 6 15
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Table 3 Correlation of clinicopathological charateristics in ILC patients with Ki67 ≤ 5% vs. ≥10%
All ILC AUS-ILC HK-ILC
Characteristics No. with
Ki67 ≤ 5 (%)
No. with
Ki67 ≥ 10 (%)
p No. with
Ki67 ≤ 5 (%)
No. with
Ki67 ≥ 10 (%)
p No. with
Ki67 ≤ 5 (%)
No. with
Ki67 ≥ 10 (%)
p
Tumor size
Median (range) 2.2 (0.18 – 12.1) 3.0 (0.20 – 11.0) 0.012 2.2 (0.5 - 12.0) 4.5 (1.5 - 11.0) 0.057 2.2 (0.18-7.0) 3.0 (0.2-9.5) 0.089
LN involvement
Negative 58 (70.7%) 15 (33.3%) <0.0005 13 (81.3%) 0 (0.0%) <0.0005 45 (68.2%) 15 (42.9%) 0.014
Positive 24 (29.3%) 30 (66.7%) 3 (18.8%) 10 (100.0%) 21 (31.8%) 20 (57.1%)
ER
Negative 5 (6.1%) 4 (8.2%) 0.654 0 (0%) 1 (7.1%) 0.277 5 (7.6%) 3 (8.6%) 0.86
Positive 77 (93.9%) 45 (91.8%) 16 (100%) 13 (92.9%) 61 (92.4%) 32 (91.4%)
PR
Negative 21 (25.6%) 11 (22.4%) 0.686 4 (25%) 1 (7.1%) 0.19 17 (25.8%) 10 (28.6%) 0.761
Positive 61 (74.4%) 38 (77.6%) 12 (75%) 13 (92.9%) 49 (74.2%) 25 (71.4%)
HER2
Negative 77 (96.3%) 42 (85.7%) 0.030 16 (100%) 13 (92.9%) 0.277 61 (95.3%) 29 (82.9%) 0.039
Positive 3 (3.8%) 7 (14.3%) 0 (0.0%) 1 (7.1%) 3 (4.7%) 6 (17.1%)
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catenin [36]; the association of low ER-β levels with
tamoxifen resistance and reduced survival benefit from
adjuvant hormone therapy [37] may therefore be clinic-
ally relevant to ILC. Unlike in ILC where the function of
the cadherin-catenin complex is irreversibly repressed
(i.e., even if E-cadherin remains expressed [38]) and hence
inhibits apoptosis [39], tamoxifen therapy of ER-positive
IDC cells appears capable of restoring E-cadherin-
dependent adhesion and augment apoptosis [40].Table 4 Correlation of clinicopathological charateristics in IDC
All IDC
Characteristics No. with
Ki67 ≤ 5 (%)
No. with
Ki67 ≥ 10 (%)
p No. with
Ki67 ≤ 5 (
Tumor size
Median (range) 1.4 (0.01 – 10.0) 2.0 (0.01 – 14.5) <0.0005 1.5 (0.2 - 6
LN involvement
Negative 177 (69.1%) 493 (56.6%) <0.0005 33 (66%
Positive 79 (30.9%) 378 (43.4%) 17 (34%
ER
Negative 13 (4.9%) 270 (30.0%) <0.0005 1 (1.8%)
Positive 252 (95.1%) 630 (70.0%) 54 (98.2%
PR
Negative 27 (10.2%) 313 (34.9%) <0.0005 3 (5.4%)
Positive 239 (89.8%) 585 (65.1%) 53 (94.6%
HER2
Negative 243 (92.0%) 650 (73.0%) <0.0005 54 (98.2%
Positive 21 (8.0%) 241 (27.0%) 1 (1.8%)E-cadherin downregulation is not specific to ILC, as it
also occurs during progression to high-Ki67 IDC tumors
such as basaloid and triple-negative subtypes, reflecting
dynamic epigenetic trans-repression of CDH1 at the
invasive tumor front as part of epithelial-mesenchymal
transition (EMT) [41]. Estradiol stimulates the latter
pro-invasive process in ductal breast cancer cells via
upregulation of TGF-β signaling and expression of EMT-
related transcription factors such as Snail [42], leading
to activation of Wnt signaling. Clinically, Snail levelspatients with Ki67 ≤ 5% vs. ≥10%
AUS-IDC HK-IDC
%)
No. with
Ki67 ≥ 10 (%)
p No. with
Ki67 ≤ 5 (%)
No. with
Ki67 ≥ 10 (%)
p
.5) 2.2 (0.2 - 14.5) <0.0005 1.3 (0.01 - 10.0) 1.9 (0.01 - 10.0) <0.0005
) 66 (46.5%) 0.018 144 (69.9%) 427 (58.6%) 0.003
) 76 (53.5%) 62 (30.1%) 302 (41.4%)
35 (21.6%) 0.001 12 (5.7%) 235 (31.8%) <0.0005
) 127 (78.4%) 198 (94.3%) 503 (68.2%)
40 (25.0%) 0.002 24 (11.4%) 273 (37.0%) <0.0005
) 120 (75.0%) 186 (88.6%) 465 (63.0%)
) 125 (78.1%) 0.001 189 (90.4%) 525 (71.8%) <0.0005
35 (21.9%) 20 (9.6%) 206 (28.2%)
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in IDC [43]. However, Snail expression is not elevated in
ILC [44], reflecting the fact that Snail expression is mainly
restricted to E-cadherin-expressing carcinoma cells [45].
The lack of EMT so implied in ILC is therefore consistent
with the inability of these irreversibly cadherin-defective
tumors to excite stromal reaction or to present with a
scirrhous phenotype [46].
How is the observed adhesion-dependent link between
ER/PR expression levels and breast cancer cell growth to
be explained at a molecular level? From a broad per-
spective, breast cancer may be subclassified into EMT-
associated ER-poor tumors with TP53 dysfunction at
one extreme, contrasting with TP53-wildtype ER-rich
tumors with predisposing primary defects of the PI3K-
Akt-mTOR anti-apoptotic pathway at the other [9]. By
including histology (IDC vs. ILC) as a subgroup variable,
however, we can further subclassify ER-positive tumors.
The ER + IDC pathway tends to be activated by early
mutations affecting the anti-apoptotic (pro-survival)
PI3K signaling pathway; the commonest such mutation
affects the PTEN gatekeeper gene, permitting secondary
ER-α and ER-β upregulation, leading in turn to Snail
induction, EMT-related TGF-β and Wnt pathway acti-
vation, BRCA1/2 and/or TP53 inactivation. Snail overex-
pression within E-cadherin-expressing carcinoma cells
directly mediates ER-α repression [47]; hence, the result-
ing EMT leads to simultaneous ER/PR decline and Ki67
elevation [48], with or without HER-family growth factor
receptor upregulation. When the EMT transactivator
Twist is co-expressed with Snail, TGF-β-dependent
E-cadherin downregulation supervenes [43], with low
E-cadherin and high Ki67 marking an especially poor-
prognostic breast cancer subgroup [49]. ER and Ki67
tend not to be co-expressed in normal breast cells,
with such co-expression only becoming detectable dur-
ing early-stage tumorigenesis and accelerating during
progression [50].
Consistent with this, others have noted that primary
IDC cell proliferation is maximal at the advancing tumor
edge [51], a finding that we have recently confirmed to
be relevant to IDC but not to ILC (AP, unpublished ob-
servations). As noted above, the defining adhesion defect
of ILC selectively impairs apoptosis/anoikis while simul-
taneously selecting for both ER-α overexpression and
PI3K pathway upregulation via secondary mechanisms
such as increased PTEN proteolysis or activating PIK3CA
mutations [52]. The primary loss of E-cadherin functional-
ity in ILC has additional consequences that distinguish its
behavior from that of ER + (or 'luminal') IDC, including
failure of Snail upregulation and hence prevention of
EMT-associated ER repression as noted above. ILC-linked
destabilization of β-catenin also prevents upregulation of
Wnt signalling, thus accounting for the ILC-associatedlack of Ki67 increase relative to IDC. This is consistent
with work showing that loss of the Wnt5a tumor suppres-
sor protein is associated with shortened survival and ER/
PR-negativity in IDC but not in ILC [53], supporting a
stronger role for Wnt activation, EMT, and ER/PR loss in
IDC than in ILC.
Although at first glance the observations above might
seem relevant only to hormonal resistance, the biology
of ILC could be equally relevant to chemotherapy resist-
ance; indeed, as mentioned earlier, there is even stronger
clinical evidence for the latter. Increasing evidence [54]
supports the view that both the adjuvant and palliative
benefits of cytotoxic therapy derive at least in part from
cell damage caused to the peritumoral stromal cells
which provide paracrine growth networks that minimise
tumor cell apoptosis. Since these paracrine loops would
seem likely to be less potent in ILC than in IDC, how-
ever, it is very plausible that the benefits of adjuvant
chemotherapy are also generally lower in ILC. A model
illustrating how the defining adhesion defect of ILC
could to underlie a breakdown in negative feedback
between ER status and tumour proliferative rate is pre-
sented in Figure 1.
Unlike other retrospective studies in which statistical
associations may arise due to selection bias or chance,
the inverse correlation scrutinized here was independ-
ently replicated in two unrelated IDC cohorts, but not in
either or both of the ILC cohorts combined. Accord-
ingly, we submit that the utility of the present results is
not limited to mere hypothesis generation, as is typically
a major weakness of retrospective analyses. Nonetheless,
there remain several important limitations to the inter-
pretation of our study. First, the number of ILC patients
was substantially lower than that of IDC patients, raising
the possibility of a type I statistical error. Second, the
histologic subset of ILC is itself heterogeneous, being
divisible into additional non-classic ILC variants such as
solid, alveolar, and pleomorphic which are associated
with higher Ki67 status and poorer prognosis; given the
relatively small size of this study, we cannot exclude that
our conclusions may be only applicable to the classical
ILC subgroup. A valuable focus for future research will
thus be to clarify whether non-classical ILC tumors
more closely resemble high-grade IDCs in their clinical
behavior and therapeutic benefit.
Third, although the differences in age and ethnicity be-
tween the AUS and HK cohorts permit some degree of
qualitative corroboration, they also raise questions about
the significance of any quantitative differences observed
between the groups; for example, are the study conclu-
sions more readily applicable to younger and/or premen-
opausal (HK) than to older and/or postmenopausal
(AUS) ILC patients, given the statistics in Table 3, and if
so, should ILC arising in older patients predisposed by
Figure 1 Model of how the differing molecular evolution of IDC and ILC could explain the loss of negative feedback between ER and
Ki67 status. See text for details.
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to be more hormone-responsive than ILC arising in youn-
ger patients? While this certainly seems plausible, further
work is needed to reach a firm conclusion on this point.
Fourth, the present study compared two arbitrarily-
defined but discontinuous Ki67 groupings of ≤5% (“slow”)
vs. ≥10% (“fast”). In contrast, recent literature has gener-
ated a consensus figure of Ki67 = 14% as a qualitative
numerical cut-off point to distinguish “faster” from
“slower” breast tumors as part of a continuous distribu-
tion [56-58]. At the time that our study was originally
designed, this cut-off convention had not been widely
adopted. Moreover, we would argue that there is an
arbitrary dimension to all such cut-offs – consider, for
example, that a 13% Ki67 tumor’s biology is likely to
differ more from a 4% Ki67 tumor than from a 15%
Ki67 tumor, irrespective of which cutoff convention isused for study purposes. Accordingly, we maintain that our
qualitative conclusions relating to “faster” and “slower”
tumors are at least as valid, if not moreso, using the
Ki67 cutoffs specified in the manuscript, given that this
splits the comparison into two unequivocally distinct
(i.e., numerically discontinuous) groups.
Finally, as with any non-centralized multicenter study,
the differences in pathology reagents and techniques used
in the two centers (see Methods) could in theory predis-
pose to an inadvertent bias of the results and conclusions.
For example, differences in the two Ki67 antibodies could
in theory have led to significant discordances in results
between the two series. In practice, however - given the
demonstrated concordance of results based on two separ-
ately derived data sets - we submit that the dual-cohort
design strengthens rather than weakens the reliability of
the two substudies’ independent yet similar conclusions.
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In summary, the present study suggests that subtle but
important functional differences are likely to distinguish
the clinical behavior and therapeutic responsiveness of
ILCs and IDCs. Whereas a rise in the Ki67 proliferation
index is typically linked to a drop in ER/PR expression
in IDC, cautioning against overreliance on hormonal
therapies, our work indicates that this molecular caveat
seldom occurs in ILC. Recent advances in understanding
of the events involved in ILC progression, and their dis-
tinction from the EMT/Wnt cascades occurring in IDC,
raise the hypothesis that mTOR inhibitors could prove
effective in restoring hormone- and/or chemosensitivity
to refractory advanced ILC tumors, as well as plausibly
improving adjuvant survival outcomes for higher-risk
ILCs being treated with these drug classes. We further
recommend specific interrogation of meta-analysis data-
bases used for randomized trials (e.g., EBCTCG) to
quantify the relative value-add of hormonal and cyto-
toxic therapies in the adjuvant and palliative manage-
ment of ILC vs. IDC.
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